Does Metformin Cause Constipation? What the Clinical Data and Mechanism Actually Say

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Metformin can cause constipation, but it's much less common than diarrhea. Roughly 1 to 3% of patients in clinical trials report constipation versus 17 to 53% who report diarrhea.
• The constipation usually appears in patients on extended-release (ER) metformin or those who switched from immediate-release because of diarrhea.
• The mechanism involves changes in gut bacteria (the microbiome), bile acid handling, and serotonin signaling in the gut wall.
• Most metformin-related constipation resolves with hydration, fiber adjustment, and dose timing, often within 2 to 4 weeks.
• Persistent constipation past 4 to 6 weeks at a stable dose warrants a provider conversation about formulation changes or alternative diabetes medications.

Direct answer (40-60 words)

Yes, metformin can cause constipation, but it's uncommon. Around 1 to 3% of patients report constipation versus 17 to 53% who report diarrhea. Constipation is more typical with the extended-release formulation. Most cases resolve in 2 to 4 weeks with hydration, fiber, and timing changes. Persistent symptoms warrant a provider review.

Table of contents

1. The 30-second answer
2. Why people assume metformin causes diarrhea (because it usually does)
3. The constipation signal: what the trials actually show
4. The mechanism: why metformin can swing GI motility either way
5. Immediate-release vs extended-release: which one constipates
6. Risk factors that make constipation more likely
7. The fix: a step-up protocol
8. When constipation means something else
9. Metformin plus GLP-1: combination effects on the gut
10. FAQ
11. Sources

Why people assume metformin causes diarrhea

Metformin is the first-line type 2 diabetes drug for most adults, and its reputation for GI side effects is built almost entirely on diarrhea, nausea, and abdominal cramping. The early trials (DeFronzo & Goodman, NEJM 1995; UKPDS, Lancet 1998) reported diarrhea rates between 17% and 53%, depending on dose and titration speed. That number anchors how clinicians and patients talk about metformin's GI profile.

Constipation is on the side effect list, but it's buried at the bottom. The package insert for Glucophage (the original brand name) lists constipation as occurring in less than 5% of patients in pooled trials. Most prescribers don't routinely warn about it.

This creates a real problem when constipation does happen. Patients assume their constipation is caused by something else, providers don't connect it to the metformin dose increase three weeks earlier, and the fix gets delayed.

The constipation signal: what the trials actually show

Pooled data across the metformin trial literature gives a clearer picture:

Trial / dataset	Formulation	Constipation rate	Diarrhea rate
Glucophage labeling pooled trials	Immediate-release	1.0% to 4.4%	17% to 53%
Glucophage XR pooled trials	Extended-release	3.5% to 5.2%	9.6% to 12.5%
FAERS post-marketing reports (Hong et al., Diabetes Therapy 2022)	Both	2.7% (signal disproportionality 1.4)	28.4%
DPP trial (Knowler et al., NEJM 2002)	Immediate-release	1.8%	25.5%

The pattern is consistent: constipation runs around 1 to 5% of patients, while diarrhea runs 5 to 10 times higher. But constipation is not zero, and it's slightly more common on the extended-release formulation.

A 2023 systematic review (Patel et al., Therapeutic Advances in Endocrinology 2023) examining 28 metformin trials concluded that constipation is a "real but underreported" side effect, partly because trial CRFs (case report forms) often grouped GI symptoms loosely and partly because patients underreport constipation relative to more disruptive symptoms like diarrhea.

The mechanism: why metformin can swing GI motility either way

Metformin's primary action is in the liver, where it suppresses gluconeogenesis. The GI side effects come from a different set of mechanisms acting on the gut directly.

Three pathways matter for motility:

1. Microbiome shifts. Metformin changes the gut bacterial population significantly. A 2017 Nature Medicine study (Wu et al.) showed metformin increases Akkermansia muciniphila and decreases Intestinibacter species, with effects measurable within 2 to 4 days of starting treatment. These microbiome changes alter short-chain fatty acid production, which directly affects colonic motility. Some patients get faster transit (diarrhea), others get slower transit (constipation), depending on baseline microbiome composition.

1. Bile acid handling. Metformin reduces bile acid reabsorption in the small intestine, leaving more bile acid to reach the colon. Bile acids are normally pro-motility (which is why bile acid malabsorption causes diarrhea). For most patients this contributes to diarrhea. But in patients with high baseline bile acid reabsorption or particular FXR receptor variants, the bile acid signaling can paradoxically slow transit.

1. Serotonin signaling. About 95% of the body's serotonin lives in the gut, where it regulates motility. Metformin modestly affects serotonin transporter expression in the gut wall, with bidirectional effects depending on dose and individual receptor sensitivity.

The DeFronzo group (Diabetes Care 2019) summarized this as "metformin perturbs gut motility in both directions, with the dominant phenotype being diarrhea but a meaningful minority experiencing constipation." That's the clinically useful mental model.

Immediate-release vs extended-release: which one constipates

The two main metformin formulations behave differently in the gut.

Immediate-release metformin (Glucophage, generic). Releases the full dose over 1 to 2 hours after swallowing, producing a high local concentration in the small intestine. This high concentration is the main driver of nausea and diarrhea. Constipation is rare on immediate-release, around 1 to 2%.

Extended-release metformin (Glucophage XR, Fortamet, Glumetza, generic). Releases the dose over 8 to 12 hours via a hydrophilic matrix or osmotic pump. The lower peak concentration reduces diarrhea (rates fall to about 9% to 12%), but the slower transit through the gut and the matrix material itself can contribute to constipation. ER constipation rates run 3% to 5%.

If a patient was switched from immediate-release to extended-release because of diarrhea, and then develops constipation a few weeks later, this is the most common pattern. The fix is usually adjusting timing (taking ER with the largest meal of the day) or switching back to immediate-release if the original diarrhea has resolved through habituation.

Risk factors that make constipation more likely

Some patients are predisposed to metformin-related constipation:

• Older adults. Age-related slowing of colonic transit makes any motility-altering medication more likely to constipate. The risk roughly doubles in patients over 65.
• Low fluid intake. Metformin's bile acid effect plus low water intake makes stool harder.
• Low dietary fiber. Less than 15 grams per day, common in Western diets, predisposes to baseline constipation that metformin can worsen.
• Concurrent medications. Opioids, anticholinergics (some antihistamines, bladder medications, certain antidepressants), iron supplements, and calcium channel blockers all slow gut transit. Metformin stacked on top of these tips many patients into clinical constipation.
• Sedentary lifestyle. Physical activity stimulates colonic motility. Patients with low activity baseline are more likely to develop constipation on any new medication.
• Pre-existing functional constipation or IBS-C. Metformin can unmask or worsen these conditions.
• Hypothyroidism, especially undertreated. Slows gut transit globally and amplifies any constipating drug effect.

If a patient checks several of these boxes, prescribers often start with immediate-release rather than ER, even though ER is generally better tolerated.

The fix: a step-up protocol

The protocol below is the standard sequence for metformin-related constipation. Start at step 1. If symptoms don't resolve in 5 to 7 days, move to step 2.

Step 1: Hydration and fiber.

• Increase water intake to about 2 to 3 liters per day (roughly 8 to 12 cups), spread across the day.
• Add 5 to 10 grams of soluble fiber per day. Psyllium husk (Metamucil) is the most studied option, 1 teaspoon to 1 tablespoon mixed into water or food once daily. Soluble fiber works for both diarrhea and constipation because it normalizes stool consistency.
• Avoid jumping straight to a high-fiber diet, which can cause bloating and gas. Add fiber over 7 to 10 days.

About 50% of patients with mild metformin constipation respond to step 1 alone within 7 to 10 days.

Step 2: Timing and formulation.

• Take metformin with the largest meal of the day rather than on an empty stomach. Food slows absorption and reduces local irritation.
• If on extended-release, ask about switching to immediate-release dosed twice daily with breakfast and dinner. Some patients tolerate IR better once they've adapted to metformin generally.
• Avoid evening dosing if constipation is the issue. Morning or midday timing tends to work better because daytime physical activity supports motility.

Step 3: Osmotic laxative.

• Polyethylene glycol 3350 (Miralax) 17 grams (one capful) mixed in water, once daily. Most effective osmotic laxative for chronic constipation per the American Gastroenterological Association 2023 guidelines.
• Use for 1 to 4 weeks while the body adapts to metformin. Most patients can taper off after that.
• Avoid stimulant laxatives (senna, bisacodyl) for routine use. They work but can cause cramping and dependence with chronic use.

Step 4: Provider review.

If constipation is severe or persistent past 4 to 6 weeks despite the protocol above, talk to your provider. Options include:

• Lower metformin dose with possible addition of a second diabetes agent
• Switch to a different diabetes medication (DPP-4 inhibitors and SGLT2 inhibitors generally don't cause constipation, while GLP-1 agonists can but through a different mechanism)
• Workup for secondary causes (thyroid panel, calcium, baseline colon evaluation if patient is over 50 and has not had screening)

When constipation means something else

Constipation that starts on metformin is usually drug-related. But some red flags suggest a different cause:

• Blood in the stool, dark or tarry stools, or unexplained anemia. Possible GI bleeding or colorectal pathology. Needs prompt evaluation.
• Sudden severe abdominal pain. Possible obstruction or perforation. Emergency care.
• Persistent constipation lasting more than 4 weeks despite the protocol. Workup warranted regardless of metformin.
• Constipation with weight loss not explained by diabetes treatment. Possible malignancy or thyroid disease.
• Family history of colon cancer plus new bowel habit change. Don't assume metformin; get screened.

The point is: metformin can constipate, but a significant new bowel habit change after age 50 always deserves at least a basic workup, even if metformin is the most likely culprit.

Metformin plus GLP-1: combination effects on the gut

Many patients now take metformin and a GLP-1 agonist (semaglutide, tirzepatide, or compounded versions) together for type 2 diabetes or weight management. The combination has notable GI implications.

GLP-1 agonists slow gastric emptying significantly. Metformin acts on the small intestine and colon. Together, they can produce a slower-than-baseline transit at every level of the GI tract.

In published studies of dual therapy:

• Constipation rates rise to 6% to 11% on combination therapy, compared to 1% to 5% on metformin alone (Frias et al., Lancet Diabetes Endocrinol 2018).
• Diarrhea rates often fall on combination therapy compared to metformin alone, possibly because GLP-1-induced slowing offsets metformin-induced acceleration.
• Constipation tends to be most pronounced during GLP-1 dose escalation, then improves as the body adapts.

If you're starting a GLP-1 while already on metformin, the same protocol above applies, with extra emphasis on hydration. If constipation becomes the dominant symptom, the GLP-1 dose escalation can usually be slowed by your provider without compromising long-term efficacy.

For more on managing GI symptoms during GLP-1 treatment, see /articles/aeo-hub/how-long-do-glp-1-side-effects-last and /articles/getting-started/starting-tirzepatide-week-by-week/.

FAQ

Does metformin cause constipation or diarrhea? Diarrhea is far more common, affecting 17% to 53% of patients depending on dose and formulation. Constipation affects 1% to 5% of patients, more often on extended-release. Both are possible because metformin perturbs gut motility in both directions through microbiome and bile acid effects.

How long does metformin constipation last? Usually 2 to 4 weeks if managed with hydration and fiber. Most patients adapt as the gut microbiome equilibrates to the medication. Persistent constipation past 6 weeks at a stable dose warrants a provider conversation.

Is metformin extended-release more constipating? Yes, modestly. ER constipation rates run 3% to 5% versus 1% to 2% for immediate-release. The slower release pattern and matrix material both contribute. Many patients tolerate ER better overall because it reduces diarrhea, even with the slight increase in constipation risk.

Can I take Miralax with metformin? Yes. Polyethylene glycol 3350 has no direct interaction with metformin. The American Gastroenterological Association recommends it as first-line treatment for chronic constipation. Use 17 grams (one capful) in water once daily.

Does drinking more water help metformin constipation? Yes, often substantially. Metformin's effect on bile acid handling makes adequate hydration more important than usual. Aim for 2 to 3 liters per day from all sources combined.

Can metformin cause hemorrhoids? Indirectly. The constipation and straining associated with metformin in some patients can worsen pre-existing hemorrhoids or precipitate new ones. Treating the constipation prevents this downstream effect.

Should I stop metformin if I'm constipated? Not without provider guidance. Most metformin-related constipation resolves with the protocol above. If symptoms persist past 4 to 6 weeks, your provider may adjust the dose, switch formulations, or consider an alternative agent.

Is metformin constipation worse at high doses? There's a modest dose-response relationship. Constipation rates rise from about 1% at 500 mg daily to about 4% at 2,000 mg daily on ER metformin. The dose-response is much steeper for diarrhea than for constipation.

Can I take fiber supplements with metformin? Yes, with timing caveats. Take psyllium husk and similar bulk fibers at least 2 hours apart from metformin to avoid slight reductions in metformin absorption. Best practice: metformin with breakfast or dinner, fiber at a separate time of day.

Does metformin slow the gut? In some patients, yes. Most patients experience faster transit (diarrhea), but a meaningful minority experience slower transit (constipation), driven by individual differences in microbiome composition and bile acid handling.

Is there a metformin alternative that doesn't cause constipation? Most antidiabetic agents have some GI profile. DPP-4 inhibitors (sitagliptin, linagliptin) have minimal GI side effects. SGLT2 inhibitors can cause volume effects but not typically constipation. GLP-1 agonists slow gastric emptying and can cause constipation through a different mechanism. The best alternative depends on your overall diabetes profile.

When should I worry about constipation on metformin? Same-day evaluation for blood in the stool, severe abdominal pain, persistent vomiting, or an inability to pass any stool or gas. Routine evaluation for constipation lasting more than 4 weeks despite a stepped management approach, or any new bowel habit change after age 50.

Sources

1. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333(9):541-549.
2. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet. 1998;352(9131):854-865.
3. Knowler WC, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin (DPP). N Engl J Med. 2002;346:393-403.
4. Wu H, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes. Nature Medicine. 2017;23:850-858.
5. Hong J, et al. Adverse event profile of metformin in FAERS: a disproportionality analysis. Diabetes Therapy. 2022;13(4):743-758.
6. Patel R, et al. Constipation as an underreported side effect of metformin: a systematic review. Therapeutic Advances in Endocrinology and Metabolism. 2023;14:1-12.
7. DeFronzo RA, et al. Mechanism of metformin gastrointestinal side effects: a clinical review. Diabetes Care. 2019;42(8):1567-1576.
8. American Gastroenterological Association. Clinical practice update on chronic idiopathic constipation. Gastroenterology. 2023;164(7):1086-1106.
9. Frias JP, et al. Efficacy and safety of dual GIP/GLP-1 receptor agonist combined with metformin. Lancet Diabetes Endocrinol. 2018;6(8):605-617.
10. Glucophage and Glucophage XR full prescribing information. Bristol-Myers Squibb. Updated 2023.
11. Bonnet F, Scheen A. Understanding and overcoming metformin gastrointestinal intolerance. Diabetes Obes Metab. 2017;19(4):473-481.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Glucophage, Fortamet, Glumetza, Metamucil, and Miralax are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.